CAJ | 학술논문

表皮生长因子受体?酪氨酸激酶抑制剂（ EGFR?TKI）是目前应用最广泛的肺癌靶向药物，但几乎所有治疗有效的患者最终都会对EGFR?TKI产生继发耐药，耐药机制主要为EGFR下游通路被再度激活。肝X受体（ LXR）属于核受体家族，多项研究表明LXR激动剂对EGFR最重要的下游通路PI3K／AKT／NF?κB多个主要环节均有不同程度的抑制作用。因此， LXR激动剂可能是逆转EGFR?TKI继发耐药的新选择。本文主要对近年来LXR激动剂对PI3K／AKT／NF?κB通路的抑制作用进行综述。
표피생장인자수체?락안산격매억제제（ EGFR?TKI）시목전응용최엄범적폐암파향약물，단궤호소유치료유효적환자최종도회대EGFR?TKI산생계발내약，내약궤제주요위EGFR하유통로피재도격활。간X수체（ LXR）속우핵수체가족，다항연구표명LXR격동제대EGFR최중요적하유통로PI3K／AKT／NF?κB다개주요배절균유불동정도적억제작용。인차， LXR격동제가능시역전EGFR?TKI계발내약적신선택。본문주요대근년래LXR격동제대PI3K／AKT／NF?κB통로적억제작용진행종술。
Epidermal growth factor receptor tyrosine kinase inhibitor( EGFR?TKI) is the most widely used drug in the targeted treatment of lung cancer. However, almost all patients who are effective to this drug will eventually develop secondary resistance to EG?FR?TKI. The main mechanism of resistance is that the EGFR associated signal pathway was again activated. The liver X receptor( LXR) belongs to the family of nuclear receptor. Many studies showed the inhibitory effects of LXR agonists on the signal pathway of PI3K/AKT/NF?κB that are important to EGFR. Therefore, LXR agonists may be a potential new choice that can reverse the secondary resist?ance of EGFR?TKI. This paper summarizes the recent findings about the inhibitory effects of LXR agonists on PI3K/AKT/NF?κB path?way.